Adverse hospital outcomes associated with the choice of empiric antibiotics in Klebsiella pneumoniae pneumonia: A retrospective observational study

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 8, 2007, Pages 642-646

  Loh, Li Cher ^a,c   Sani, Rosdara Masayuni Mohd ^a   Samad, Nor Izran Hanim Abdul ^a   Raman, Sree ^b   Thayaparan, Tarmizi ^b   Kumar, Shalini ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b Seremban Hospital   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

In vitro resistance; Malaysia

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; PNEUMONIA; RISK FACTOR;

EID: 34548498432     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Liam CK, Lim KH, Wong CM. Community-acquired pneumonia in patients requiring hospitalization. Respirology 2001;6:259-64.
2. Hooi LN, Looi I, Ng AJ. A study on community acquired pneumonia in adults requiring hospital admission in Penang. Med J Malaysia 2001;56:275-84.
3. Loh LC, Khoo SK, Quah SY, Visvalingam V, Radhakrishna A, Vijayasingham P, et al. Adult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admission. Respirology 2004;9:379-86.
4. Wattanathum A, Chaoprasong C, Nunthapisud P, Chantaratchada S, Limpairojn N, Jatakanon A, et al. Community-acquired pneumonia in Southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003;123:1512-9.
5. Lim TK. Emerging pathogens for pneumonia in Singapore. Ann Acad Med Singapore 1997;26:651-8.
6. Hui KP, Chin NK, Chow K, Brownlee A, Yeo TC, Kumarasinghe G, et al. Prospective study of the aetiology of adult community acquired bacterial pneumonia needing hospitalisation in Singapore. Singapore Med J 1993;34:329-34.
7. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998;11:589-603.
8. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7.
9. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81.
10. Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003;31:608-16.
11. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9.
12. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
13. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56:IV1-64.
14. Hsueh PR. Guidelines for the management of lower respiratory tract infections in Asia. Infect Dis Clin Pract 2002;11:S12-S19.
15. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
16. Brancati FL, Chow JW, Wagener MM, Vacarello SJ, Yu VL. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993;342:30-3.
17. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002;15:163-7.
18. Modai J. Empiric therapy of severe infections in adults. Am J Med 1990;88:12S-17S.
19. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
20. Lautenbach E, Patel JB, Biker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71.
21. Biedenbach DJ, Lewis MT, Jones RN. In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35:277-83.